Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

48 results about "Mutant genotype" patented technology

Identification of white leghorns red plumage mutagenic mutant genotype and cultivation method for supporting system of red plumage pink shell layer chickens

The present invention discloses a method for breeding the commercial strains of red feather pink-shell laying hens. It provides a primer pair for identifying the red feather causative mutation homozygous genotype of white leghorn chickens, which is composed of the single-stranded DNA molecule shown in Sequence 2 of the Sequence List and the single-stranded DNA molecule shown in Sequence 3 of the list. After the primer was designed according to the upstream and downstream nucleotide sequences of the 18,288,303rd deoxynucleotide in the positive-sense strand of the 11th chromosome as shown in the sequence information of the chicken reference genome Gallus_gallus-4.0 version published in NCBI, the genotype (SNP) at this site is tested through the restriction fragment length polymorphism, the genotype of the site (SNP) was tested through the restriction fragment length polymorphism; the offspring hens obtained by cross breeding the homogenous female parent (the homogenous female parent was obtained through expanded propagation of the white leghorn chickens with the red feather causative mutation homozygous genotype) and the Rhode Island Red rooster as a male parent are all of red feather phenotype, meeting the market demands and enjoying a broad prospect for promotion.
Owner:BEIJING HUADU YUKOU POULTRY

Therapeutic and diagnostic methods dependent on cyp2a enzymes

InactiveUS20070254921A1BiocideNervous disorderCytochromeTobacco Dependences
A method of regulating the activity of human cytochrome P450 isozyme CYP2A6 to control nicotine metabolism or decrease to production of carcinogens from procarcinogens, such as those present in tobacco smoke, in an individual by selectively inhibiting CYP2A6. Various prophylactic (i.e., prevention and treatment) compositions and methods are also described, including an improved oral nicotine composition and method comprising the use of nicotine together with an inhibitor of the CYP2A6 enzyme. Furthermore, it has been discovered that the presence in an individual of a mutant allele of human cytochrome P450 enzyme CYP2A6 (referred to throughout this specification as “CYP2A6” for brevity) is predictive of an individual who: (i) has a decreased risk of becoming a smoker, (ii) will smoke less if he / she becomes dependent, and / or (iii) may be at relatively lower risk for cancer due to both decreased smoke exposure and decreased CYP2A6-mediated activation of tobacco smoke and other procarcinogenic substrates. This invention provides diagnostic methods for predicting tobacco dependence risk and risk for cancers related to CYP2A6 substrates in an individual by analysing for the presence of a mutant genotype for human cytochrome P450 enzyme CYP2A6 in an individual, ranging from gene duplication (multiple copies of CYP2A6) to single or even no copies due to null alleles or gene deletion.
Owner:NICOGEN

Insertion mutation detection method and system based on new-generation sequencing data

The invention belongs to the technical field of genome sequencing, and discloses an insertion mutation detection method based on new-generation sequencing data. The method comprises the steps: when amutation generation site is determined, a region where insertion mutation occurs certainly generates a split reading section, aiming at the characteristics that insertion variation types such as new sequence insertion, sequence series multiplication and sequence dispersion multiplication are different in distribution of missing variation and inverted mutation split reading sections, constructing avirtual reference sequence by utilizing partial matching, complete matching and unmatched read segment information after determining the insertion mutation generation type and site, and comparing thevirtual reference sequence with the original reference sequence to obtain related information of the insertion sequence; and obtaining a mutant genotype by utilizing the copy number state information. According to the invention, the problem of inaccurate insertion mutation point judgment can be solved; the problem of omission caused by insertion mutation detection of an SR method can be solved; the problem that in the prior art, repeated sequences may cause detection errors can be solved.
Owner:XIDIAN UNIV

Breeding method for culturing good-taste and brown stripe-resisting rice

The invention relates to a breeding for culturing good-taste and brown stripe-resisting rice and belongs to the field of genetic improvement of rice and application of biological technology. The method comprises the following steps of: selecting Wujing 13 and Guangdong 194 for matched hybridization; performing individual mixed harvest in the F2 and F3 generations, and performing the molecular mark auxiliary selection of dark albumen mutant genes and brown stripe-resisting genes at the F4 and F5 generations to obtain the double-gene homozygote, of which the dark albumen mutant genotype is Wx-mqWx-mq and the brown stripe-resisting genotype is Stv-biStv-bi; and performing the selection of yield and agronomic character at following generations until the new variety of high-yield rice, namely Nanjing 5055, with stabile and consistent agronomic character, good taste and brown stripe resistance is cultured in the F7 generation. The variety of rice has the advantages of high yield, brown stripe resistance, the combination of the softness of glutinous rice and the elasticity of non-glutinous rice, excellent taste and quality and wide application prospect in proper plantations of riverside areas and southern part of Jiangsu Province.
Owner:JIANGSU ACAD OF AGRI SCI

Muscovy duck egg laying performance associated gene SMAD3 molecular marker screening method

A muscovy duck egg laying trait associated gene SMAD3 molecular marker screening method comprises the following steps: (1) carrying out DNA extraction: extracting female muscovy duck genome DNA in anegg laying period by adopting a phenol-chlorine method, and then determining an OD value and concentration of the purity of the genome DNA; (2) carrying out primer design: carrying out SMAD3 gene amplification primer design by applying NCBI online software and Primer 5.0, and sending a primer sequence to a related biological company for synthesis; (3) carrying out PCR amplification: adopting a 15[mu]L reaction system, setting PCR amplification conditions, carrying out PCR amplification, and carrying out electrophoresis detection on a product by using 1% agarose gel; (4) sequencing amplification product fragments and screening SNP sites; and (5) directly sequencing and typing the SNP mutation sites, carrying out correlation analysis on the SNP mutation sites and the egg laying performance,and determining the SNP closely correlated with the egg laying performance. When the molecular marker is applied to the muscovy duck seed selection and breeding process, the mutant genotype of the gene SMAD3 associated with the muscovy duck egg laying performance detected by the method is used as the molecular marker.
Owner:GUIZHOU UNIV

CYP2A enzymes and their use in therapeutic and diagnostic method

A method of regulating the activity of human cytochrome P450 isozyme CYP2A6 to control nicotine metabolism or decrease the production of carcinogens from procarcinogens, such as those present in tobacco smoke, in an individual by selectively inhibiting CYP2A6. Various prophylactic (i.e., prevention and treatment) compositions and methods are also described, including an improved oral nicotine composition and method comprising the use of nicotine together with an inhibitor of the CYP2A6 enzyme. Furthermore, it has been discovered that the presence in an individual of a mutant allele of human cytochrome P450 enzyme CYP2A6 (referred to throughout this specification as 'CYP2A6' for brevity) is predictive of an individual who: (1) has a decreased risk of becoming a smoker, (ii) will smoke less if he / she becomes dependent, and / or (iii) may be at relatively lower risk for cancer due to both decreased smoke exposure and decreased CYP2A6 -mediated activation of tobacco smoke and other procarcinogenic substrates. This invention provides diagnostic methods for predicting tobacco dependence risk and risk for cancers related to CYP2A6 substrates in an individual by analyzing for the presence of a mutant genotype for human cytochrome P450 enzyme CYP2A6 in an individual, ranging from gene duplication (multiple copies of CYP2A6) to single or even no copies due to null alleles or gene deletion.
Owner:NICOGEN

Therapeutic and diagnostic methods dependent on CYP2A enzymes

InactiveUS6908631B1BiocideNervous disorderCytochromeTobacco Dependences
A method of regulating the activity of human cytochrome P450 isozyme CYP2A6 to control nicotine metabolism or decrease the production of carcinogens from procarcinogens, such as those present in tobacco smoke, in an individual by selectively inhibiting CYP2A6. Various prophylactic (i.e., prevention and treatment) compositions and methods are also described, including an improved oral nicotine composition and method comprising the use of nicotine together with an inhibitor of the CYP2A6 enzyme. Furthermore, it has been discovered that the presence in an individual of a mutant allele of human cytochrome P450 enzyme CYP2A6 (referred to throughout this specification as “CYP2A6” for brevity) is predictive of an individual who: (1) has a decreased risk of becoming a smoker, (ii) will smoke less if he / she becomes dependent, and / or (iii) may be at relatively lower risk for cancer due to both decreased smoke exposure and decreased CYP2A6 -mediated activation of tobacco smoke and other procarcinogenic substrates. This invention provides diagnostic methods for predicting tobacco dependence risk and risk for cancers related to CYP2A6 substrates in an individual by analyzing for the presence of a mutant genotype for human cytochrome P450 enzyme CYP2A6 in an individual, ranging from gene duplication (multiple copies of CYP2A6) to single or even no copies due to null alleles or gene deletion.
Owner:NICOGEN

Test probes, common oligonucleotide chips, nucleic acid detection method, and their uses

High-throughput detection for the interesting base or the mutation site in the nucleic acid sample can be achieved by the linear test probe pairs P1 and P2. The test probe pairs P1 and P2 respectively comprise either of the flanking complementary sequences which are adjacent to the interesting base or the mutation site in the nucleic acid sample. When the test probe pairs P1, P2 are annealed and hybridized to the nucleic acid sample, a gap will be generated at the interesting base or the mutation site position between the probe pairs and the sample. Divide the annealed hybrid sample into four equal reaction systems to which add dATP, dTTP, dCTP, dGTP, respectively. The test probe pairs P1 and P2 will be ligated into one single probe when adding the complementary nucleotide system under the DNA polymerase or ligase. After purified and amplified, the generated single probes are hybridized to the corresponding area in a common oligonucleotide microarray. The generated single probe will give a signal in the hybrid area, and therefore detect and analyze the hybrid signal to determine the base type or the mutation genotype at the detection position. The invention can be applied to the re-sequencing the target nucleic acid sequence, the detection and analysis for the mutation, insertion, or deletion sites of a known nucleic acid sequence, and the genotyping of the pathogenic microorganism.
Owner:SHANXI LIFEGEN

Therapeutic and Diagnostic Methods Dependent on CYP2A Enzymes

A method of regulating the activity of human cytochrome P450 isozyme CYP2A6 to control nicotine metabolism or decrease to production of carcinogens from procarcinogens, such as those present in tobacco smoke, in an individual by selectively inhibiting CYP2A6. Various prophylactic (i.e., prevention and treatment) compositions and methods are also described, including an improved oral nicotine composition and method comprising the use of nicotine together with an inhibitor of the CYP2A6 enzyme.Furthermore, it has been discovered that the presence in an individual of a mutant allele of human cytochrome P450 enzyme CYP2A6 (referred to throughout this specification as “CYP2A6” for brevity) is predictive of an individual who: (i) has a decreased risk of becoming a smoker, (ii) will smoke less if he / she becomes dependent, and / or (iii) may be at relatively lower risk for cancer due to both decreased smoke exposure and decreased CYP2A6-mediated activation of tobacco smoke and other procarcinogenic substrates. This invention provides diagnostic methods for predicting tobacco dependence risk and risk for cancers related to CYP2A6 substrates in an individual by analysing for the presence of a mutant genotype for human cytochrome P450 enzyme CYP2A6 in an individual, ranging from gene duplication (multiple copies of CYP2A6) to single or even no copies due to null alleles or gene deletion.
Owner:NICOGEN

Use of multiple target nucleic acid detection method using clamping probe and detection probe

The present invention relates to an application of a target nucleic acid detection method using a clamping probe and a detection probe. The method of the present invention can effectively detect a small amount of variation or a specific gene sequence contained in a sample by selective amplification and detection of a trace amount of a target gene to be detected while inhibiting amplification of wild-type genes or undesired genes. Also, it is possible to determine a large number of genotypes at the same time through a melting curve analysis. In particular, the method can be used for diagnosis, prognosis and monitoring of the medical condition of a disease, treatment efficacy evaluation, and for aiding nucleic acid and protein delivery studies and so on, through a very small amount of a mutant genotype that is confirmed at a high detection sensitivity. The method of the present invention comprises a step for evaluating the detection of biomarkers such as EGFR, KRAS, NRAS etc. and the presence of mutations of biomarkers using invasive specimens such as tissues as well as non-invasive specimens (blood, urine, sputum, stool, saliva, and cells). The presence of the biomarker and mutations provides a method used for monitoring of the entire cycle of a related disease, disease prognosis and prediction, decision of disease treatment strategy, disease diagnosis / early diagnosis, disease prevention, and development of disease therapeutics.
Owner:PANAGENE INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products